American Journal of Cardiology
Volume 78, Issue 3 , Pages 336-340 , 1 August 1996

Effects of Enalapril on Tissue Factor in Patients With Uncomplicated Acute Myocardial Infarction*

Received 8 January 1996 ,Accepted 4 March 1996.

References 

  1. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1–8
  2. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 1991;66:67–79
  3. Carson SD, Brozna JP. The role of tissue factor in the production of thrombin. Blood Coagul Fibrinolysis. 1993;4:281–292
  4. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captorpril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669–677
  5. The SOLVD Investigators . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691
  6. Hamsten A, De Faire U, Blomback M. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557–1563
  7. Gram J, Jesperssen J. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulin characteristics: a risk group among survivors of acute myocardial infarction. Thromb Haemost. 1987;57:136–139
  8. Sakamoto T, Yasue H, Ogawa H, Misumi I, Masuda T. Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol. 1992;70:271–276
  9. Masuda T, Yasue H, Ogawa H, Misumi I, Sakamoto T, Okubo H, et al. Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J. 1992;124:314
  10. Vaugghan DE, Shen C, Lazos SA. Angiotensin II induces plasminogen activator inhibitor (PAI-1) in vitro (abstr). Circulation 1992;86 (suppl I):I-557.
  11. Ridker PM, Gabouly CL, Comlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin (II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function). Circulation. 1993;87:1969–1973
  12. Wright RA, Flapan AD, Alberti KGM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24:67–73
  13. Leatham EW, Bath PMW, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J. 1995;73:10–13
  14. Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrissey JH, et al. Differential expression of tissue factor protein in atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91:619–622
  15. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson T. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. J Clin Invest. 1993;91:547–552
  16. Nakamura S, Goto A, Takemoto S, Mizuguti J, Funatsu A. Monoclonal antibodies to human tissue factor (abstr). Thromb Haemost 1991;65:1216.
  17. Nakamura S, Kamikubo Y, Okajima K, Asakura H, Nakamura K. Plasma tissue factor: its sensitive assay and characterization (abstr). Thromb Haemost. 1993;69:744
  18. Cushuman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol. 1971;20:1637–1648
  19. Kasahara Y, Ashihara Y. Colorimetry of angiotensin-converting enzyme activity in serum. Clin Chem. 1981;27:1922–1925
  20. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1988;47:1–9

PII: S0002-9149(96)00288-3

American Journal of Cardiology
Volume 78, Issue 3 , Pages 336-340 , 1 August 1996

Article Tools

* Image Usage & Resolution